Ubrelvy and Emgality Comparison

Ubrelvy®(ubrogepant)	Emgality®(galcanezumab-gnlm)
Prescription Only Ubrelvy is a medication that adults can use to treat acute migraine attacks. It works by blocking CGRP, a protein believed to contribute to migraine attacks by causing pain, blood...	Prescription Only Emgality is a medication that can be self-administered once a month by injecting it subcutaneously under the skin. It is used for migraine prevention in adults and can also be...
Administration
Oral. Learn more.	Subcutaneous. Learn more.
Dosing
50 mg or 100 mg as needed. Maximum daily dose: 200 mg. Severe Hepatic or Severe Renal Impairment: 50 mg.. Learn more.	Migraine: 240 mg loading dose (120 mg x 2) followed by 120 mg monthly. . Learn more.
Latin Shorthand
50 mg PRN or 100 mg PRN. Severe Renal Impairment: 50mg.. Learn more.	240 mg LD (120 mg x 2) then 120 mg/mo.. Learn more.
Out-Of-Pocket Costs With Copay Card
$0. Learn more.	$0. Learn more.
Annual Cap
Maximum savings of $50 per pill for up to 13 prescription fills.. Learn more.	$4900. Learn more.
Assistance Expiration
13 prescription fills. Learn more.	12 months. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most common adverse reactions (at least 2% and greater than placebo) were nausea and somnolence.. Learn more.	The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions. . Learn more.
Mechanism of Actions (MoA)
CGRP Antagonist. Learn more.	CGRP Antagonist. Learn more.
Special Populations
Is it safe to take UBRELVY during pregnancy? There are no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women. Patients should be encouraged to enroll in the pregnancy exposure registry that monitors outcomes in women who become pregnant while taking UBRELVY by calling 1-833-277-0206 or visiting http://empresspregnancyregistry.com. What is the risk of birth defects or miscarriage when taking UBRELVY during pregnancy? In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The estimated rate of major birth defects (2.2% -2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. However, no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women is available. What are the clinical considerations when taking UBRELVY during pregnancy? Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy. What does animal data suggest about the use of UBRELVY during pregnancy? In animal studies, adverse effects on embryofetal development were observed following administration of ubrogepant during pregnancy or during pregnancy and lactation at doses greater than those used clinically and which were associated with maternal toxicity. No adverse effects on embryofetal development were observed when ubrogepant was administered to pregnant rats during the period of organogenesis. However, no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women is available. What is the risk of taking UBRELVY while breastfeeding? There are no data on the presence of ubrogepant in human milk, the effects of ubrogepant on the breastfed infant, or the effects of ubrogepant on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for UBRELVY and any potential adverse effects on the breastfed infant from UBRELVY or from the underlying maternal condition. Is it safe to use UBRELVY in pediatric patients? Safety and effectiveness in pediatric patients have not been established. Are there any pharmacokinetic differences between elderly and younger patients when taking UBRELVY? Pharmacokinetic studies have shown no clinically significant differences between elderly and younger patients when taking UBRELVY. Was the use of UBRELVY studied in elderly patients? Clinical studies of UBRELVY did not include enough elderly patients to determine if they respond differently from younger patients. Dose selection for elderly patients should be cautious and typically start at the low end of the dosing range. How does hepatic impairment affect the exposure to UBRELVY? In patients with mild, moderate, or severe hepatic impairment, exposure to UBRELVY was increased by 7%, 50%, and 115%, respectively. No dose adjustment is necessary for mild or moderate hepatic impairment. However, for patients with severe hepatic impairment, dose adjustment is recommended. How does renal impairment affect the use of UBRELVY? Renal impairment has a minor effect on the clearance of UBRELVY. No dose adjustment is needed for patients with mild or moderate renal impairment. For those with severe renal impairment (CLcr 15-29 mL/min), dose adjustment is necessary. Patients with end-stage renal disease (CLcr <15 mL/min) should avoid the use of UBRELVY.	What is the Pregnancy Exposure Registry for EMGALITY? The Pregnancy Exposure Registry is a program that monitors pregnancy outcomes in women who have been exposed to EMGALITY during pregnancy. It is designed to collect information on any potential risks to the developing fetus. How can pregnant women enroll in the Pregnancy Exposure Registry? Pregnant women can enroll in the registry by calling 1-833-464-4724 or by contacting the company at www.migrainepregnancyregistry.com. What is the estimated risk of major birth defects and miscarriage in the general population and among women with migraine? The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively, in the general population. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Are there any known risks associated with the use of EMGALITY during pregnancy? There are no adequate data on the developmental risk associated with the use of EMGALITY in pregnant women. However, animal studies have shown that administration of galcanezumab-gnlm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects on development. Can EMGALITY be used during lactation? There are no data on the presence of galcanezumab-gnlm in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMGALITY and any potential adverse effects on the breastfed infant from EMGALITY or from the underlying maternal condition. Is EMGALITY safe for pediatric use? Safety and effectiveness in pediatric patients have not been established. Is there any difference in the response to EMGALITY in geriatric patients compared to younger patients? Clinical studies of EMGALITY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

Ubrelvy®(ubrogepant)

Emgality®(galcanezumab-gnlm)

Prescription Only

Ubrelvy is a medication that adults can use to treat acute migraine attacks. It works by blocking CGRP, a protein believed to contribute to migraine attacks by causing pain, blood...

Prescription Only

Emgality is a medication that can be self-administered once a month by injecting it subcutaneously under the skin. It is used for migraine prevention in adults and can also be...

Dosage & Administration

Administration

Oral. Learn more.

Subcutaneous. Learn more.

Dosing

50 mg or 100 mg as needed. Maximum daily dose: 200 mg. Severe Hepatic or Severe Renal Impairment: 50 mg.. Learn more.

Migraine: 240 mg loading dose (120 mg x 2) followed by 120 mg monthly. . Learn more.

Latin Shorthand

50 mg PRN or 100 mg PRN. Severe Renal Impairment: 50mg.. Learn more.

240 mg LD (120 mg x 2) then 120 mg/mo.. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$0. Learn more.

Annual Cap

Maximum savings of $50 per pill for up to 13 prescription fills.. Learn more.

$4900. Learn more.

Assistance Expiration

13 prescription fills. Learn more.

12 months. Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most common adverse reactions (at least 2% and greater than placebo) were nausea and somnolence.. Learn more.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions. . Learn more.

Mechanism of Actions (MoA)

CGRP Antagonist. Learn more.

Special Populations

Is it safe to take UBRELVY during pregnancy?

There are no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women. Patients should be encouraged to enroll in the pregnancy exposure registry that monitors outcomes in women who become pregnant while taking UBRELVY by calling 1-833-277-0206 or visiting http://empresspregnancyregistry.com.

What is the risk of birth defects or miscarriage when taking UBRELVY during pregnancy?

In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The estimated rate of major birth defects (2.2% -2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. However, no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women is available.

What are the clinical considerations when taking UBRELVY during pregnancy?

Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.

What does animal data suggest about the use of UBRELVY during pregnancy?

In animal studies, adverse effects on embryofetal development were observed following administration of ubrogepant during pregnancy or during pregnancy and lactation at doses greater than those used clinically and which were associated with maternal toxicity. No adverse effects on embryofetal development were observed when ubrogepant was administered to pregnant rats during the period of organogenesis. However, no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women is available.

What is the risk of taking UBRELVY while breastfeeding?

There are no data on the presence of ubrogepant in human milk, the effects of ubrogepant on the breastfed infant, or the effects of ubrogepant on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for UBRELVY and any potential adverse effects on the breastfed infant from UBRELVY or from the underlying maternal condition.

Is it safe to use UBRELVY in pediatric patients?

Safety and effectiveness in pediatric patients have not been established.

Are there any pharmacokinetic differences between elderly and younger patients when taking UBRELVY?

Pharmacokinetic studies have shown no clinically significant differences between elderly and younger patients when taking UBRELVY.

Was the use of UBRELVY studied in elderly patients?

Clinical studies of UBRELVY did not include enough elderly patients to determine if they respond differently from younger patients. Dose selection for elderly patients should be cautious and typically start at the low end of the dosing range.

How does hepatic impairment affect the exposure to UBRELVY?

In patients with mild, moderate, or severe hepatic impairment, exposure to UBRELVY was increased by 7%, 50%, and 115%, respectively. No dose adjustment is necessary for mild or moderate hepatic impairment. However, for patients with severe hepatic impairment, dose adjustment is recommended.

How does renal impairment affect the use of UBRELVY?

Renal impairment has a minor effect on the clearance of UBRELVY. No dose adjustment is needed for patients with mild or moderate renal impairment. For those with severe renal impairment (CLcr 15-29 mL/min), dose adjustment is necessary. Patients with end-stage renal disease (CLcr <15 mL/min) should avoid the use of UBRELVY.

What is the Pregnancy Exposure Registry for EMGALITY?

The Pregnancy Exposure Registry is a program that monitors pregnancy outcomes in women who have been exposed to EMGALITY during pregnancy. It is designed to collect information on any potential risks to the developing fetus.

How can pregnant women enroll in the Pregnancy Exposure Registry?

Pregnant women can enroll in the registry by calling 1-833-464-4724 or by contacting the company at www.migrainepregnancyregistry.com.

What is the estimated risk of major birth defects and miscarriage in the general population and among women with migraine?

The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively, in the general population. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.

Are there any known risks associated with the use of EMGALITY during pregnancy?

There are no adequate data on the developmental risk associated with the use of EMGALITY in pregnant women. However, animal studies have shown that administration of galcanezumab-gnlm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects on development.

Can EMGALITY be used during lactation?

There are no data on the presence of galcanezumab-gnlm in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMGALITY and any potential adverse effects on the breastfed infant from EMGALITY or from the underlying maternal condition.

Is EMGALITY safe for pediatric use?

Safety and effectiveness in pediatric patients have not been established.

Is there any difference in the response to EMGALITY in geriatric patients compared to younger patients?

Clinical studies of EMGALITY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

Ubrelvy® Alternatives